Succinylcholine Dosing in Myasthenia Gravis

Introduction to Myasthenia Gravis and Succinylcholine

The American College of Anesthesiologists recommends avoiding succinylcholine entirely in patients with myasthenia gravis (MG) due to unpredictable and potentially dangerous responses at the neuromuscular junction, and instead using rocuronium at doses ≥0.9 mg/kg as the neuromuscular blocking agent of choice 1

Patients with MG have reduced acetylcholine receptors at the neuromuscular junction, making their response to depolarizing agents like succinylcholine highly variable and unpredictable 1, 2
MG patients are at risk of prolonged paralysis due to altered receptor dynamics, even with standard dosing 1

The American Society of Anesthesiologists recommends a dose of 0.9-1.2 mg/kg IV rocuronium for rapid sequence intubation in MG patients, providing excellent intubating conditions within 60 seconds 3, 1
The duration of action of rocuronium is 30-60 minutes, which is acceptable given its superior safety profile compared to succinylcholine 4, 1
Sugammadex should be immediately available for reversal if needed, particularly important in MG patients where prolonged paralysis is especially problematic 4, 5

If succinylcholine must be used despite MG, expect significantly reduced dose requirements, with MG patients requiring only 50% of the normal dose due to receptor downregulation 1
Neuromuscular monitoring is mandatory to assess depth of blockade and guide reversal in MG patients 4, 3

The American College of Anesthesiologists advises against assuming normal dosing applies to MG patients, as they have fundamentally altered neuromuscular junction physiology 1, 2
The Society of Critical Care Medicine recommends having sugammadex immediately accessible when using rocuronium in MG patients, and not proceeding without reversal agents available 4, 5